EUVIMEDOpdag EUVIMED
Crossref

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

Carmen Martínez iD, Esther Carcelero, Antonio Gutiérrez, Esther Sancho, Josep Maria Martí-Tutusaus, Laura Magnano, Pablo Mozas iD, Francesc Fernández-Avilés iD, María Gabriela Antelo, Xavier Setoain, Sonia Rodríguez, Jordi Esteve

Hematological Oncology · 2024

DOI: 10.1002/hon.3299 ↗

At a glance

Journal article in Hematological Oncology, 2024. Written by Carmen Martínez and 11 co-authors. Institution: Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain. Major MEDLINE topics: Hodgkin Disease, Brentuximab Vedotin, Bleomycin, Antineoplastic Combined Chemotherapy Protocols. Cited 4 times so far (Crossref); 14 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Patients with advanced‐stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG‐PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression‐free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A‐AVD escalation treatment outcomes for 15 iPET‐positive patients post‐ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17‐month follow‐up, all patients are alive, 87% in complete remission, and 1‐year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A‐AVD escalation may be a viable alternative.

Subjects

MeSH terms (MEDLINE)

Hodgkin DiseaseBrentuximab VedotinBleomycinAntineoplastic Combined Chemotherapy ProtocolsPositron-Emission TomographyDoxorubicinVinblastineDacarbazineHumansMaleFemaleAdultMiddle AgedYoung AdultNeoplasm StagingAgedTreatment OutcomeFollow-Up Studies

Author keywords

ABVDHodgkin lymphomabrentuximab vedotinfirst‐line chemotherapypositive PET interim

Substances

Brentuximab VedotinBleomycinDoxorubicinVinblastineDacarbazine

Authors and institutions

  • Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain.
  • August Pi i Sunyer Biomedical Research Institute-IDIBAPS, Barcelona, Spain.
  • Farmacology Department, Center of Biomedic Diagnosis, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Hematology Department, Hospital de Granollers, Barcelona, Spain.
  • Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain.

ORCID profiles: Carmen Martínez, Pablo Mozas, Francesc Fernández-Avilés

Cite

APA

Martínez, C., Carcelero, E., Gutiérrez, A., Sancho, E., Martí-Tutusaus, J. M., Magnano, L., Mozas, P., Fernández-Avilés, F., Antelo, M. G., Setoain, X., Rodríguez, S., & Esteve, J. (2024). Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD. Hematological Oncology. https://doi.org/10.1002/hon.3299

Vancouver

Martínez C, Carcelero E, Gutiérrez A, Sancho E, Martí-Tutusaus JM, Magnano L, et al. Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD. Hematological Oncology. 2024. doi:10.1002/hon.3299

BibTeX
@article{Martnez2024,
  author = {Martínez, Carmen and Carcelero, Esther and Gutiérrez, Antonio and Sancho, Esther and Martí-Tutusaus, Josep Maria and Magnano, Laura and Mozas, Pablo and Fernández-Avilés, Francesc and Antelo, María Gabriela and Setoain, Xavier and Rodríguez, Sonia and Esteve, Jordi},
  title = {Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3299}
}
Start for free →